Jia Wang – InmunoES

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

6 de February de 2026 by Jia Wang

BackgroundAnti-CD19 chimeric antigen receptor (CAR)-T cell therapy has demonstrated clinical potential in treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, enhancing its therapeutic efficacy remains a significant cha…

Single-cell atlas of the tumor immune microenvironment across syngeneic murine models

14 de November de 2025 by Jia Wang

The tumor immune microenvironment plays a critical role in tumor progression and responses to immunotherapy. Nevertheless, its cellular complexity and heterogeneity remain incompletely understood. In this study, we employed high-resolution single-cell …

Tumor-derived SEMA7A regulates fatty acid oxidation in the tumor-associated macrophages to promote the progression of non-small cell lung cancer

11 de September de 2025 by Jia Wang

Non-small cell lung cancer (NSCLC) is an aggressive cancer with a poor prognosis. Despite the success of therapies for NSCLC, more investigations of new biomarkers for patient selection are urgently needed. Semaphorin 7A (SEMA7A), a soluble tumor-deriv…

301 Moved Permanently